Loading news...
Exploring Strategic Moves in the Health Sciences Sector Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for
Hussman Strategic Advisors Inc. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 21,000 shares of the company's stock, valued at approximately $2,948,000. Several other institutional investors have also recently added to or
SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2 (VMAT2).
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Conference Call and Webcast Scheduled for Wednesday, February 11 SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatment VMAT2 occupancy is a key measurement thought to be associated with drug response in involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea SAN DIEGO, Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) capsules and AUSTEDO XR (deutetrabenazine) at therapeutic doses. Results from the study confirmed that both compounds engage VMAT2; however, INGREZZA demonstrated significantly higher VMAT2 target occupancy and greater potency.
Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Robeco Institutional Asset Management B.V. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 86.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,185 shares of the company's stock after purchasing an additional 13,087 shares
Cerity Partners LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 76.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 103,626 shares of the company's stock after purchasing an additional 44,852 shares during the
Pre-Market Stock Futures: The futures are trading lower on Thursday after investors and traders tapped the brakes on the 2026 new year rally, as only the Nasdaq was able to grind out another gain, finishing the session at 23,584, up 0.16. After exploding higher to print new all-time highs on Tuesday, both the Dow Jones... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technolgies, and More.
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m.
Stanley Laman Group Ltd. trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 40.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,354 shares of the company's stock after selling 17,167 shares during the period. Stanley
Cwm LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 218.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 83,724 shares of the company's stock after buying an additional 57,435 shares during the period. Cwm
Neurocrine Biosciences Inc. (NASDAQ: NBIX) on Monday shared data from its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP).
Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.
SAN DIEGO , Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not meet primary or key secondary endpoints. The primary objective of the study was to assess improvement in chorea, a type of involuntary movement, in individuals with DCP.
Assenagon Asset Management S.A. cut its stake in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 22.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,947 shares of the company's stock after selling 13,280 shares during the period. Assenagon Asset Management
Neurocrine Biosciences, Inc. (NASDAQ: NBIX - Get Free Report) Director Leslie Norwalk sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $152.23, for a total transaction of $761,150.00. Following the completion of the sale, the director directly owned 7,429 shares
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript
Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities Reviewed Positive Data Across Late-Stage Neuropsychiatry Pipeline Including Osavampator and Direclidine; Topline Phase 3 Data from Both Programs Expected in 2027 Announced Expansion of CRF Platform as Foundation of New Class of Medicines for Metabolic Diseases, Including Obesity SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a new chapter in its research and development strategy, designed to fuel the Company's next era for growth and deliver long-term value. Neurocrine highlighted this business strategy during its 2025 R&D Day at its headquarters in San Diego, CA.